Figure 1.

JAK1/2 Inhibitor May Ameliorate High-Output Heart Failure Associated With Myeloproliferative Disease

MPD with JAK1/2 mutation often causes elevation of inflammatory cytokines and extramedullary hematopoiesis reflected in marked splenomegaly in the middle left panel. These 2 factors sometimes result in HOHF (typically presented with cardiomegaly shown in the lower left panel). Theoretically, JAK1/2 inhibition prohibits this pathway, and may ameliorate HOHF associated with MPD. Improved RHC data after the initiation of JAK1/2 inhibitor in our case (upper right table) support this hypothesis. BNP = brain natriuretic peptide; CI = cardiac index; HOHF = high-output heart failure; MPD = myeloproliferative disease; PAP = pulmonary artery pressure; PCWP = pulmonary capillary wedge pressure; RAP = right atrial pressure; RHC = right heart catheterization.